Over a month ago
Recommendations
BTIG analyst Thomas…
BTIG analyst Thomas Shrader lowered the firm's price target on BioAtla to $13 from $68 and keeps a Buy rating on the shares. The firm thinks it is too early to abandon the story based on a surprising cohort, and that the BA3011 + CPI combination arm is the only negative readout to date with an ORR of 12.5% with one CR in eight patients, far below the 44% seen in the monotherapy arm in CPI-failed NSCLC, the analyst tells investors in a research note. While the data is "very strange," rogue cohorts are possible in salvage patients, the firm says.
Show Hide Related Items >> <<
02/27/23 BioAtla president Scott Smith departs 02/27/23 Viatris annouces appointment of Smith as CEO 02/23/23 BioAtla announces FDA clearance of IND for BA3182 01/10/23 BioAtla provides clinical program updates, 2023 milestones 03/27/23 JMP Securities BioAtla price target lowered to $12 from $17 at JMP Securities 03/24/23 H.C. Wainwright BioAtla price target lowered to $17 from $20 at H.C. Wainwright 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 03/23/23 BioAtla reports Q4 net loss $27.5M vs. net loss of $23.4M last year 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning
Recommendations
JMP Securities analyst…
JMP Securities analyst Reni Benjamin lowered the firm's price target on BioAtla to $12 from $17 and keeps an Outperform rating on the shares, citing a discounted EPS and revenue multiple analysis. BioAtla shares are attractively priced, especially on the heels of a greater than 50% decline in market cap earlier this year, and it has four distinct assets soon to be in the clinic, an abundance of data readouts over the next 6-12 months, and a cash position of $215.5M, the analyst tells investors in a research note.
Show Hide Related Items >> <<
02/27/23 BioAtla president Scott Smith departs 02/27/23 Viatris annouces appointment of Smith as CEO 02/23/23 BioAtla announces FDA clearance of IND for BA3182 01/10/23 BioAtla provides clinical program updates, 2023 milestones 03/24/23 H.C. Wainwright BioAtla price target lowered to $17 from $20 at H.C. Wainwright 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 03/23/23 BioAtla reports Q4 net loss $27.5M vs. net loss of $23.4M last year 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning
Recommendations
H.C. Wainwright lowered…
H.C. Wainwright lowered the firm's price target on BioAtla to $17 from $20 and keeps a Buy rating on the shares post the Q4 results. BioAtla had approximately $216M in cash and cash equivalents, which is sufficient to support operations into 2025, the analyst tells investors in a research note.
Show Hide Related Items >> <<
02/27/23 BioAtla president Scott Smith departs 02/27/23 Viatris annouces appointment of Smith as CEO 02/23/23 BioAtla announces FDA clearance of IND for BA3182 01/10/23 BioAtla provides clinical program updates, 2023 milestones 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse 03/23/23 BioAtla reports Q4 net loss $27.5M vs. net loss of $23.4M last year 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning
Earnings
Reports cash and cash…
Reports cash and cash equivalents as ofDecember 31 were$215.5M, compared to $245M as of December 31, 2021. We expect current cash and cash equivalents will be sufficient to fund planned operations including all ongoing CAB product development programs into 2025. ."BioAtla made excellent progress in 2022 across all five of our ongoing Phase 2 trials targeting multiple tumor types for our two CAB-ADC product candidates, BA3011 and BA3021, as well as with our other promising CAB clinical asset, BA3071 , and we are excited to advance our potentially first-in-class CAB bispecific T-cell engager antibody, CAB-EpCAMxCAB-CD3 (BA3182) into the clinic following its recent IND clearance," said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. "Going forward, there are several important milestones and value inflection points that we are on track to achieve and communicate throughout 2023, including the advancement of our Phase 2, part 2 potentially registrational BA3011 trial in NSCLC, completion of the Phase 2 study for BA3021 in NSCLC enabling FDA discussions regarding a potential registrational trial and the initiation of a phase 2 trial for BA3071. All of our trials are targeting areas of high unmet medical need where our CAB technology has the potential to further distinguish itself from other technologies in terms of both efficacy and safety. As we advance these important drug candidates toward registration, we continue to manage our resources to ensure that the company progresses through these and other important milestones into 2025."
Show Hide Related Items >> <<
02/27/23 BioAtla president Scott Smith departs 02/27/23 Viatris annouces appointment of Smith as CEO 02/23/23 BioAtla announces FDA clearance of IND for BA3182 01/10/23 BioAtla provides clinical program updates, 2023 milestones 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning
Conference/Events
Pharmaceuticals Analyst…
Pharmaceuticals Analyst Schott and Biotech Analysts Fye, Cheng & Rama, along with Key Opinion Leaders Dr. Hatim Husain of UCSD and Dr. Joshua Sabari of NYU College of Medicine, discuss their perspectives on the lung cancer landscape (relevant companies MRK, AZN, GILD, SGEN, NVCR, NUVL, BCAB) on an Analyst/Industry conference call to be held on March 16 at 10 am. Webcast Link
Show Hide Related Items >> <<
03/13/23 Pfizer to acquire Seagen for $229 per share in cash 03/13/23 Pfizer to acquire Seagen for $229 per share in cash 03/09/23 Seagen, Astellas says China's NMPA accepts BLA for enfortumab vedtoin 02/28/23 Seagen CFO sells $3.65M in common stock 03/01/23 Novocure announces reimbursement of Optune with TMZ 03/01/23 Novocure announces final patient enrolled in METIS study 02/15/23 Novocure: Final patient enrolled TTFields combo study to treat pancreatic cancer 01/19/23 Novocure announces organizational changes 02/22/23 Nuvalent treatment of certain non-small cell lung cancer granted orphan status 12/13/22 Nuvalent announces publication detailing design of NVL-520 10/28/22 Nuvalent reports preliminary Phase 1 clinical data from ARROS-1 trial 03/10/23 Merck says Phase 2/3 CCTG IND.227/KEYNOTE-483 trial met primary endpoint 03/08/23 Opko Health enters exclusive worldwide license agreement with Merck 03/06/23 Merck says MK-0616 'significantly reduced' LDL-C in Phase 2b study 03/06/23 Merck: FDA approves IM route of administration for MMRV family of vaccines 02/22/23 Gilead presents PoC data for investigational combination of lenacapavir, bNAbs 02/21/23 Gilead reports 'positive data' from real-world studies of Veklury 02/21/23 Gilead says new data from four collaborative HIV studies reported at CROI 02/17/23 Kite CEO Christi Shaw leaving Gilead at end of March 02/27/23 BioAtla president Scott Smith departs 02/27/23 Viatris annouces appointment of Smith as CEO 02/23/23 BioAtla announces FDA clearance of IND for BA3182 01/10/23 BioAtla provides clinical program updates, 2023 milestones 03/09/23 AstraZeneca announces ADAURA trial meets secondary endpoint 03/09/23 AstraZeneca announces AEGEAN trial demonstrated statistical significance 03/09/23 AstraZeneca says Tagrisso showed 'strong' overall survival benefit in trial 03/09/23 AstraZeneca says Imfinzi significantly improved event-free survival in AEGEAN 03/13/23 Wells Fargo Merck downgraded at Wells Fargo on valuation, lack of catalysts 03/13/23 Wells Fargo Merck downgraded to Equal Weight from Overweight at Wells Fargo 03/10/23 Berenberg Merck price target raised to $130 from $125 at Berenberg 03/09/23 Guggenheim Merck price target raised to $123 from $116 at Guggenheim 03/15/23 Berenberg AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg 03/07/23 Guggenheim Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs 03/07/23 Evercore ISI Mineralys Therapeutics initiated with an Outperform at Evercore ISI 02/21/23 UBS AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS 03/13/23 Stifel Arcellx initiated with a Buy at Stifel 02/14/23 Mizuho Gilead price target raised to $101 from $88 at Mizuho 02/10/23 TD Cowen Gilead price target raised to $95 from $90 at Cowen 02/03/23 Baird Gilead price target raised to $80 from $69 at Baird 03/15/23 Morgan Stanley Seagen downgraded to Equal Weight from Overweight at Morgan Stanley 03/14/23 RBC Capital Seagen price target raised to $229 from $155 at RBC Capital 03/14/23 SVB Securities Seagen price target raised to $229 from $141 at SVB Securities 03/14/23 Oppenheimer Seagen price target raised to $229 from $210 at Oppenheimer 02/23/23 H.C. Wainwright Novocure price target lowered to $130 from $135 at H.C. Wainwright 01/17/23 Piper Sandler Novocure price target raised to $80 from $70 at Piper Sandler 01/06/23 Piper Sandler Medicare paying 9% more for Novocure's Optune system in 2023, says Piper 01/06/23 Wells Fargo Novocure downgraded to Equal Weight from Overweight at Wells Fargo 01/18/23 Wedbush Wedbush bullish on Nuvalent, initiates with an Outperform 01/17/23 Wedbush Nuvalent initiated with an Outperform at Wedbush 10/28/22 BMO Capital Nuvalent price target raised to $50 from $28 at BMO Capital 10/28/22 Piper Sandler Nuvalent's NVL-520 phase 1 data 'about as good as hoped,' says Piper Sandler 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse 02/15/23 Seagen sees FY23 revenue $2.14B-$2.24B, consensus $2.3B 02/15/23 Seagen reports Q4 EPS (80c), consensus ($1.04) 10/27/22 Seagen raises FY22 revenue $1.82B-$1.865B from $1.71B-$1.795B 10/27/22 Seagen reports Q3 EPS ($1.03), consensus (95c) 02/23/23 Novocure reports Q4 EPS (36c), consensus (30c) 01/09/23 Novocure sees Q4 revenue $128M, consensus $129.14M 10/27/22 Novocure reports Q EPS (25c), consensus (26c) 03/16/23 Nuvalent reports Q4 EPS (49c), consensus (43c) 11/10/22 Nuvalent reports Q3 EPS (41c), consensus (44c) 02/28/23 NGM Biopharmaceuticals reports Q4 EPS (45c), consensus (51c) 02/02/23 Merck sees FY23 adjusted EPS $6.80-$6.95, consensus $7.36 02/02/23 Merck reports Q4 adjusted EPS $1.62, consensus $1.54 02/01/23 Notable companies reporting before tomorrow's open 02/02/23 Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73 02/02/23 Gilead reports Q4 adjusted EPS $1.67, consensus $1.49 02/02/23 Notable companies reporting after market close 12/20/22 Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 11/10/22 AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage 11/10/22 AstraZeneca reports Q3 core EPS $1.67, YTD core EPS $5.28
Over a quarter ago
Hot Stocks
BioAtla (BCAB) announced…
BioAtla (BCAB) announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as CEO at Viatris (VTRS). Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company.
Show Hide Related Items >> <<
12/14/22 Viatris says emissions reduction targets approved by SBTi 12/13/22 Calliditas Therapeutics enters exclusive Nefecon license agreement with Viatris 11/29/22 Viatris closes biosimilars transaction with Biocon Biologics 02/27/23 Viatris annouces appointment of Smith as CEO 02/23/23 BioAtla announces FDA clearance of IND for BA3182 01/10/23 BioAtla provides clinical program updates, 2023 milestones 11/04/22 BioAtla announces $65M underwritten offering of common stock 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse 02/17/23 BMO Capital Viatris downgraded to Market Perform from Outperform at BMO Capital 02/01/23 Barclays Viatris price target lowered to $15 from $16 at Barclays 01/27/23 Jefferies Viatris upgraded to Buy at Jefferies on increased visibility 01/27/23 Jefferies Viatris upgraded to Buy from Hold at Jefferies 02/27/23 Viatris sees FY23 revenue $15.5B-$16B, consensus $15.57B 02/27/23 Viatris reports Q4 EPS 83c, consensus 72c 11/07/22 Viatris backs FY22 revenue view $16.2B-$16.7B, consensus $16.5B 11/07/22 Viatris reports Q3 EPS 29c, consensus 84c 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 10/12/22 Viatris weighing sale of $3B European OTC assets, Bloomberg reports 11/09/22 Biotech Alert: Searches spiking for these stocks today 11/07/22 What You Missed On Wall Street On Monday 11/07/22 What You Missed On Wall Street This Morning 10/12/22 What You Missed On Wall Street On Wednesday 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning 01/27/23 Viatris call volume above normal and directionally bullish 01/24/23 Viatris put volume heavy and directionally bearish 01/19/23 Viatris call volume above normal and directionally bullish 01/06/23 Viatris call volume above normal and directionally bullish
Hot Stocks
Viatris (VTRS) announced…
Viatris (VTRS) announced that as it prepares to enter Phase 2 of its previously announced strategic plan in 2024, Scott Smith has been appointed by its Board of Directors to lead the execution of that plan as Viatris' new Chief Executive Officer, effective April 1, 2023. In the interim, current CEO Michael Goettler will be working closely with Smith to support a smooth transition and will then depart as CEO and as a member of the board. Smith has been a member of the Viatris Board since December 2022 and is a deeply knowledgeable senior global biotechnology and pharmaceutical executive with more than 35 years of experience. Most recently, he served as President of BioAtla, Inc. (BCAB)
Show Hide Related Items >> <<
12/14/22 Viatris says emissions reduction targets approved by SBTi 12/13/22 Calliditas Therapeutics enters exclusive Nefecon license agreement with Viatris 11/29/22 Viatris closes biosimilars transaction with Biocon Biologics 11/10/22 Viatris wins court decision invalidating AstraZeneca's Symbicort patent 02/23/23 BioAtla announces FDA clearance of IND for BA3182 01/10/23 BioAtla provides clinical program updates, 2023 milestones 11/04/22 BioAtla announces $65M underwritten offering of common stock 02/17/23 BMO Capital Viatris downgraded to Market Perform from Outperform at BMO Capital 02/01/23 Barclays Viatris price target lowered to $15 from $16 at Barclays 01/27/23 Jefferies Viatris upgraded to Buy at Jefferies on increased visibility 01/27/23 Jefferies Viatris upgraded to Buy from Hold at Jefferies 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse 02/27/23 Viatris sees FY23 revenue $15.5B-$16B, consensus $15.57B 02/27/23 Viatris reports Q4 EPS 83c, consensus 72c 11/07/22 Viatris backs FY22 revenue view $16.2B-$16.7B, consensus $16.5B 11/07/22 Viatris reports Q3 EPS 29c, consensus 84c 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 10/12/22 Viatris weighing sale of $3B European OTC assets, Bloomberg reports 11/09/22 Biotech Alert: Searches spiking for these stocks today 11/07/22 What You Missed On Wall Street On Monday 11/07/22 What You Missed On Wall Street This Morning 10/12/22 What You Missed On Wall Street On Wednesday 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning 01/27/23 Viatris call volume above normal and directionally bullish 01/24/23 Viatris put volume heavy and directionally bearish 01/19/23 Viatris call volume above normal and directionally bullish 01/06/23 Viatris call volume above normal and directionally bullish
Hot Stocks
BioAtla announced that…
BioAtla announced that the U.S. Food and Drug Administration, FDA, has cleared its investigational new drug, IND, application to evaluate BA3182 for the treatment of advanced adenocarcinoma. BioAtla plans to initiate and advance a Phase 1 dose-escalation and expansion clinical study in 2023. "While we continue to advance our CAB-ADC and CAB immuno-oncology antibodies across multiple tumor types, we are now expanding our pipeline with the recent FDA IND clearance for our potentially first-in-class bispecific antibody, BA3182," said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla. "Our goal is to continue executing and pursuing indications with large unmet medical need that potentially have the highest impact for patients and our shareholders worldwide. We believe our current cash position is sufficient to fund our operations into 2025 through several value generating milestones for our current clinical programs as well as the initiation of the BA3182 clinical trial."
Show Hide Related Items >> <<
01/10/23 BioAtla provides clinical program updates, 2023 milestones 11/04/22 BioAtla announces $65M underwritten offering of common stock 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning
On The Fly
Get caught up quickly on…
Show Hide Related Items >> <<
01/04/23 AT&T CFO Desroches says demand 'remains healthy' 01/04/23 AT&T CFO sees earnings and free cash flow growth in 2023 12/23/22 AT&T, BlackRock Alternatives to form commercial fiber platform joint venture 12/06/22 AT&T COO says company continues to see healthy demand 01/10/23 TD Synnex, Authomize partner for ITDR platform 01/10/23 TD Synnex announces $1B share repurchase pact 01/10/23 TD Synnex boosts dividend 17% to 35c per share 12/12/22 BIO-key, TD Synnex partner for identity-bound biometric MFA solutions $17.25 / +8.615 (+99.77%)
01/09/23 Sotera Health settles ethylene oxide litigation in Illinois for $408M 11/21/22 Sotera Health business Sterigenics issues statement on Fornek trial 11/21/22 Sotera Health trading resumes 11/21/22 Sotera Health jumps after Sterigenics found not liable for woman's cancer 08/04/22 Shake Shack sees FY22 domestic company-operated openings 35-40 07/13/22 Chairman of Shake Shack Daniel Meyer buys over $831K in shares RYAM Rayonier Advanced Materials 01/10/23 Rayonier Advanced Materials falls -28.3% 01/10/23 Rayonier Advanced Materials falls -19.7% 01/10/23 Rayonier Advanced Materials falls -11.6% 12/29/22 Rayonier: Force majeure by nat gas provider had $4M EBITDA impact to company 01/05/23 Iridium to partner t with Qualcomm on satellite messaging and emergency services 01/04/23 Visteon, Qualcomm collaborate on development of digital cockpit 11/02/22 Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates 12/05/22 PepsiCo announces new global packaging goal 10/28/22 PepsiCo senior VP Gallagher sells 5,558 common shares 10/24/22 Keurig Dr Pepper names Sudhanshu Priyadarshi as CFO, effective November 14 10/13/22 Little Caesars, MTN DEW announce gaming combo, in-game items 01/10/23 Oak Street Health rises 28.5% 01/10/23 Oak Street Health rises 27.6% 01/10/23 Oak Street Health rises 31.8% 01/09/23 Oak Street Health jumps 26% after Bloomberg reports potential acquisition by CVS 01/10/23 Intel unveils 4th Gen Xeon Scalable processors, Xeon CPU Max Series 01/09/23 Mondelez to release special edition Oreos with Xbox images 01/09/23 Microsoft acquires datacenter infrastructure company Fungible 01/06/23 NetEase acquires SkyBox Labs, terms not disclosed 01/10/23 Senator Sanders says Moderna COVID vaccine pricing shows 'unacceptable' greed 01/09/23 Moderna expects minimum Covid-19 vaccine sales of $5B in 2023 01/09/23 Moderna announces updates on mRNA pipeline 01/05/23 CytomX Therapeutics updates business, announces 2023 relationship with Moderna 12/08/22 Tyson Foods appoints Melanie Boulden as CGO 11/14/22 Berkshire Hathaway adds TSMC, exits STORE Capital in Q3 10/13/22 Laser Photonics announces implementation of CleanTech Handheld Laser Blasting 10/10/22 VPX Sports, maker of Bang Energy drinks, seeks Chapter 11 bankruptcy protection $216.86 / +15.675 (+7.79%)
10/06/22 Icon selected by BARDA to execute an anthrax vaccine clinical trial 01/10/23 Frontline rises 24.7% 01/10/23 Frontline rises 17.1% 01/10/23 Frontline rises 21.7% 01/09/23 Frontline terminates combination agreement with Euronav 01/10/23 CVS Health saw flu vaccinations 'elevate a little bit' in latter part of 2022 01/10/23 CVS Health sees Signify Health deal closing in 1H, CEO says 01/10/23 CVS Health sees FY23 MA membership growth in LSD-MSD range 01/10/23 CVS Health repurchased 15M shares during Q4 at average share price of $99.99 01/10/23 Coinbase to cut workforce by about 950 employees in further restructuring 01/05/23 Cathie Wood's ARK Investment bought 172K shares of Coinbase today 01/04/23 Coinbase, NYDFS reach agreement to resolve compliance investigation 01/04/23 NY DFS announces $100M settlement with Coinbase 10/27/22 Capital One falls 5% to $97.15 after Q3 earnings miss estimates 10/12/22 BJ's Wholesale introduces new partnership with Capital One 08/24/22 Truist Financial appoints Scott Stanzel as EVP, CCO 07/21/22 Capital One drops 5% to $108.50 after Q2 results miss estimates 12/13/22 Match Group up 8% after Bloomberg report on Apple App store plans 11/13/22 Fly Intel: Top five weekend stock stories 11/10/22 Google expands its user choice billing pilot 11/09/22 Bumble down 18% after reporting Q3 earnings, giving Q4 guidance 01/10/23 BioAtla provides clinical program updates, 2023 milestones 11/04/22 BioAtla announces $65M underwritten offering of common stock 01/10/23 Bed Bath & Beyond says identified additional $80M-$100M saving opportunity 01/10/23 Bed Bath & Beyond reports Q3 SSS down 32% 01/10/23 Bed Bath & Beyond reports liquidity of approximately $0.5B 01/10/23 Bed Bath & Beyond says Q3 net loss included $100.7M non-cash impairment charges 12/08/22 Evogene to receive $3.5M payment from Bayer 11/08/22 Bayer launches LifeHub Monheim 10/12/22 Regeneron announces U.S. FDA accepted for priority review the sBLA for EYLEA 09/27/22 GXO Logistics expands warehouse services for Bayer 01/10/23 ViaSat receives certificate in China to install connectivity in Boeing aircrafts 01/10/23 Boeing reports 774 commercial orders in 2022 01/10/23 Boeing announces total Q4 deliveries 152 aircraft 01/10/23 Boeing delivered 110 737s in Q4, 2 747s 12/20/22 EU opens antitrust probe into Broadcom's proposed $61B VMware bid 12/15/22 Broadcom announces availability of CA 1 Flexible Storage soution 12/08/22 Broadcom reports Q4 cash from operations $4.583B, free cash flow $4.461M 12/08/22 Broadcom raises quarterly dividend 12% to $4.60 per share 01/10/23 Amazon expands Buy with Prime service, introduces Reviews from Amazon 01/09/23 Mattel's Fisher-Price re-announces recall of 4.7M Rock 'n Play Sleepers 01/06/23 Ceva's AFE solution now Alexa Voice Service qualified 01/10/23 Sarissa Capital submits notice to call Special Meeting of Amarin shareholders 01/10/23 Amarin expects cash to support continued operations 01/10/23 Amarin announces 2022 achievements, 2023 priorities 01/10/23 Amarin appoints Stewart to board of directors 10/19/22 Ally Financial sees Q4 as earnings 'low point' 10/19/22 Ally Financial down 7.7% after Q3 earnings and revenue miss 10/19/22 Ally Financial sees uncertainty ahead 10/18/22 Ally Financial says Jennifer LaClair departed from CFO position 01/02/23 Albertsons granted expedited review of special dividend restraining order 12/21/22 Albertsons says Washington State Supreme Court Set to hear appeal on February 9 12/21/22 Washington state AG files lawsuits against pharmacy chains over opioid crisis 12/06/22 Kroger expects to complete Albertsons merger in 'early 2024' 01/10/23 Jamf Holding helps 71,000 customers succeed with Apple 01/09/23 Qualcomm down 1% after Bloomberg report on Apple taking modem in-house 01/04/23 Apple fined EUR 8M by France's CNIL 12/26/22 Fly Intel: Top five weekend stock stories 01/09/23 Agilent authorizes $2B buyback authorization 01/09/23 Agilent invests $725M for manufacturing of therapeutic nucleic acids 01/06/23 Agilent, Akoya to develop diagnostic solutions for tissue analysis 12/15/22 Agilent VP Ancher-Jensen sells $4.6M of shares 01/11/23 Mizuho Coinbase workforce cut does not fix number one problem, says Mizuho 01/11/23 BofA Coinbase downgraded to Underperform at BofA on below-Street 2023 view 01/11/23 BofA Coinbase downgraded to Underperform from Neutral at BofA 01/09/23 Jefferies Coinbase initiated with a Hold at Jefferies 01/10/23 Wedbush December quarter checks for Microsoft's Azure 'stable,' says Wedbush 01/10/23 Barclays Microsoft price target lowered to $280 from $296 at Barclays 01/09/23 Piper Sandler Microsoft price target lowered to $247 from $265 at Piper Sandler 01/05/23 Oppenheimer Oppenheimer sees Microsoft leveraging ChatGPT white-space potential 01/11/23 KeyBanc KeyBanc says iPhone survey shows supply partial recovery, some shortages remain 01/11/23 KeyBanc KeyBanc keeps Overweight on Apple, says user growth more important 01/11/23 Barclays Apple price target lowered to $133 from $144 at Barclays 01/10/23 Piper Sandler Piper Sandler sees no strategic reason for Apple to insource Wi-Fi combo chip 01/10/23 BofA Broadcom loss of Apple socket immaterial for 2-plus years, says BofA 12/27/22 Piper Sandler Piper reveals top cloud automation software picks heading into 2023 01/09/23 BWS Financial Iridium price target raised to $75 from $60 at BWS Financial 01/11/23 Baird Bed Bath & Beyond price target lowered to $1.00 from $2.00 at Baird 01/05/23 Wells Fargo Wells halves Bed Bath & Beyond target to $1, says bankruptcy may be 'imminent' 11/28/22 Wedbush Black Friday winners Include Best Buy, losers include Pets, says Wedbush 09/30/22 Odeon Capital Odeon upgrades Bed Bath & Beyond to Hold with things 'moving in right direction' 01/10/23 DA Davidson Accolade price target lowered to $14 from $16 at DA Davidson 01/10/23 Canaccord Accolade price target lowered to $14 from $17 at Canaccord 12/27/22 Piper Sandler Piper views TriCare T-5 contract awards as neutral for Accolade 10/04/22 Needham Accolade price target raised to $15 from $12 at Needham 01/11/23 JPMorgan Boeing price target raised to $207 from $200 at JPMorgan 01/10/23 Morgan Stanley Boeing downgraded to Equal Weight from Overweight at Morgan Stanley 01/03/23 Baird Boeing price target raised to $250 from $210 at Baird 12/14/22 Susquehanna Boeing price target raised to $217 from $185 at Susquehanna 01/10/23 Citi Citi adds AT&T, Equinix to 'Positive Catalyst Watch List' 01/10/23 Wells Fargo AT&T upgraded to Overweight from Equal Weight at Wells Fargo 12/27/22 Raymond James Raymond James sees 'solid benefits' to AT&T from BlackRock venture 12/23/22 KeyBanc AT&T-BlackRock fiber JV a 'material positive' for Dycom, says KeyBanc 01/10/23 KeyBanc KeyBanc upgrades Bumble on confidence in revenue growth 01/09/23 KeyBanc Bumble upgraded to Overweight from Sector Weight at KeyBanc 12/12/22 BofA Bumble initiated with a Buy at BofA 12/08/22 UBS UBS starts Bumble at Neutral, sees international opportunity offset saturation 01/10/23 JPMorgan Capital One price target lowered to $124 from $126 at JPMorgan 01/10/23 Jefferies Capital One downgraded to Hold from Buy at Jefferies 01/05/23 Stephens Capital One downgraded to Underweight at Stephens on auto lending concerns 01/05/23 Stephens Capital One downgraded to Underweight from Equal Weight at Stephens 01/10/23 JPMorgan Ally Financial price target lowered to $27 from $30 at JPMorgan 01/10/23 Jefferies Ally Financial downgraded to Hold from Buy at Jefferies 01/09/23 Piper Sandler Ally Financial upgraded to Neutral from Underweight at Piper Sandler 01/10/23 Wells Fargo Wells Fargo upgrades Agilent to Overweight, raises price target to $170 01/10/23 Wells Fargo Agilent upgraded to Overweight from Equal Weight at Wells Fargo 01/06/23 Gordon Haskett wonders if Guardant could be 'shoehorned' into Agilent search 11/22/22 Jefferies Agilent price target raised to $168 from $158 at Jefferies 01/10/23 Stifel Oak Street Health, CVS deal would make sense for both companies, says Stifel 01/10/23 Piper Sandler Takeout report adds 'intrigue' to Oak Street story, says Piper Sandler 01/05/23 Wells Fargo NY, NC opportunities could be 1% tailwind to CVS EPS, says Wells Fargo 01/04/23 BofA Amwell upgraded to Buy at BofA with anchor clients signed 11/21/22 Raymond James Oak Street Health downgraded to Market Perform from Outperform at Raymond James 11/21/22 Raymond James Oak Street Health downgraded to Market Perform from Outperform at Raymond James 01/06/23 MKM Partners MKM Partners sees WWE as 'very attractive asset' if it goes for sale 01/05/23 BofA Amazon layoffs 'not a positive signal,' but 'good for sentiment,' says BofA 01/04/23 UBS Amazon.com price target lowered to $125 from $165 at UBS 01/04/23 Needham Needham cuts Overstock.com to Hold, sees company as 'share donor' post pandemic 12/20/22 Atlantic Equities Coca-Cola, Pepsi remain preferred beverage names at Atlantic Equities 12/06/22 Deutsche Bank Coca-Cola price target raised to $62 from $59 at Deutsche Bank 11/04/22 Redburn PepsiCo initiated with a Sell at Redburn 10/26/22 UBS Coca-Cola price target raised to $68 from $63 at UBS 12/07/22 Argus PepsiCo price target raised to $206 from $195 at Argus 12/06/22 Deutsche Bank PepsiCo price target raised to $186 from $181 at Deutsche Bank 01/06/23 Morgan Stanley Bayer downgraded to Equal Weight from Overweight at Morgan Stanley 01/05/23 Roth MKM Dare Bioscience resumed with a Buy at Roth Capital 01/03/23 JPMorgan Bayer downgraded to Neutral from Overweight at JPMorgan 12/05/22 BofA Bayer downgraded to Neutral from Buy at BofA 01/05/23 Morgan Stanley Morgan Stanley sees Moderna's phase 3 RSV vaccine data as catalyst-driven idea 12/20/22 Piper Sandler Moderna price target raised to $217 from $214 at Piper Sandler 12/19/22 Jefferies Moderna upgraded to Buy from Hold at Jefferies 12/16/22 Morgan Stanley Moderna price target raised to $209 from $170 at Morgan Stanley $17.25 / +8.615 (+99.77%)
01/10/23 Wolfe Research Sotera Health upgraded to Outperform at Wolfe Research after Illinois settlement 01/10/23 Wolfe Research Sotera Health upgraded to Outperform from Peer Perform at Wolfe Research 01/10/23 Barclays Sotera Health double-upgraded to Overweight from Underweight at Barclays 01/10/23 Wolfe Research Sotera Health 'to rock' with 'massive overhang' removed, says Wolfe Research 01/10/23 Stifel Euronav NV downgraded to Hold from Buy at Stifel 11/29/22 Jefferies Frontline price target raised to $17 from $16 at Jefferies 10/27/22 Deutsche Bank Frontline price target raised to $15 from $12 at Deutsche Bank 09/06/22 Deutsche Bank Frontline price target raised to $12 from $7 at Deutsche Bank 01/06/23 Jefferies Jefferies upgrades 'intriguing small cap value play' Amarin to Buy 01/06/23 Jefferies Amarin upgraded to Buy from Hold at Jefferies 05/06/22 JPMorgan JPMorgan downgrades Amarin to sell on headwinds in U.S., Europe 05/06/22 JPMorgan Amarin downgraded to Underweight from Neutral at JPMorgan 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse RYAM Rayonier Advanced Materials 01/09/23 RBC Capital Rayonier Advanced Materials cut to Sector Perform at RBC Capital on valuation 01/09/23 RBC Capital Rayonier Advanced downgraded to Sector Perform from Outperform at RBC Capital 10/13/22 BofA Rayonier Advanced Materials price target lowered to $1.90 from $2.60 at BofA 07/18/22 RBC Capital Rayonier Advanced Materials upgraded to Outperform at RBC Capital 01/05/23 Barclays Shake Shack price target lowered to $42 from $46 at Barclays 12/21/22 Wedbush Shake Shack downgraded to Neutral from Outperform at Wedbush 12/21/22 Wedbush Shake Shack downgraded to Neutral from Outperform at Wedbush 11/07/22 Deutsche Bank Shake Shack price target raised to $56 from $53 at Deutsche Bank $216.86 / +15.675 (+7.79%)
12/21/22 Baird Icon price target lowered to $260 from $265 at Baird 11/09/22 BofA Icon upgraded to Buy from Neutral at BofA 10/18/22 Deutsche Bank Icon price target lowered to $280 from $295 at Deutsche Bank 10/10/22 Guggenheim Iqvia price target lowered to $234 from $246 at Guggenheim 01/04/23 Wells Fargo Albertsons price target lowered to $22 from $30 at Wells Fargo 12/19/22 Credit Suisse Albertsons assumed with Restricted rating at Credit Suisse 12/06/22 Bernstein Albertsons initiated with an Outperform at Bernstein 12/05/22 Jefferies Kroger price target raised to $50 from $45 at Jefferies 01/11/23 Credit Suisse TD Synnex price target raised to $109 from $103 at Credit Suisse 12/21/22 Citi Citi reveals top IT hardware stock picks for 2023 10/12/22 Raymond James TD Synnex added to Analyst Current Favorites list at Raymond James 10/04/22 RBC Capital TD Synnex initiated with a Sector Perform at RBC Capital 10/20/22 AT&T raises FY22 adjusted cont ops EPS view to '$2.50 or higher' 10/20/22 AT&T reports Q3 adjusted EPS 68c, consensus 61c 10/19/22 Notable companies reporting before tomorrow's open 01/10/23 TD Synnex sees Q1 EPS $2.60-$3.00, consensus $3.05 01/10/23 TD Synnex reports Q4 EPS $3.44, consensus $2.91 09/27/22 TD Synnex sees Q4 EPS $2.70-$3.10, consensus $2.73 09/27/22 TD Synnex reports Q3 EPS $2.74, consensus $2.73 $17.25 / +8.615 (+99.77%)
11/02/22 Sotera Health lowers FY22 adjusted EPS view to 91c-95c from 93c-97c 11/02/22 Sotera Health reports Q3 adjusted EPS 23c, consensus 22c 08/04/22 Sotera Health narrows FY22 adjusted EPS guidance to 93c-97c from 93c-99c 08/04/22 Sotera Health reports Q2 adjusted EPS 27c, consensus 24c 01/10/23 Shake Shack reports preliminary Q4 revenue $238.5M, consensus $237.56M 11/03/22 Shake Shack reports Q3 adjusted EPS (6c), consensus (6c) 08/04/22 Shake Shack sees Q3 revenue $221M-$226.5M consensus $245M 08/04/22 Shake Shack reports Q2 EPS 0c vs. 5c last year RYAM Rayonier Advanced Materials 11/01/22 Rayonier Advanced Materials reports Q3 EPS 45c, two estimates 10c 08/03/22 Rayonier Advanced Materials reports Q2 continuing ops EPS (39c), consensus (16c) 11/02/22 Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42 11/02/22 Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13 11/02/22 Notable companies reporting after market close 07/27/22 Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23 10/12/22 PepsiCo raises FY22 core EPS view to approx. $6.73 from $6.63 10/12/22 PepsiCo raises FY22 core constant currency EPS growth view to 10% from 8% 10/12/22 PepsiCo reports Q3 core EPS $1.97, consensus $1.84 10/11/22 Notable companies reporting before tomorrow's open 01/09/23 Oak Street Health sees FY23 revenue $3.0B-$3.15B, consensus $3.05B 01/09/23 Oak Street Health raises FY22 revenue view to at or above $2.155B 11/07/22 Oak Street Health reports Q3 EPS (56c), consensus (61c) 08/02/22 Oak Street Health raises FY22 revenue $2.125B-$2.145B from $2.1B-$2.135B 10/25/22 Microsoft sees FX decreasing total revenue growth by 5% in FY23 10/25/22 Microsoft reports Q1 EPS $2.35, consensus $2.30 10/25/22 Notable companies reporting after market close 07/26/22 Microsoft sees FY23 revenue growth in double digits, consensus $225.98B 11/03/22 Moderna reports Q3 EPS $2.53, consensus $3.29 11/02/22 Notable companies reporting before tomorrow's open 08/03/22 Moderna reports Q2 GAAP EPS $5.24, consensus $4.55 10/25/22 Coca-Cola sees FY22 comparable EPS up 6%-7%, consensus $2.46 10/25/22 Coca-Cola sees 1% impact to FY22 net revenues, operating income from Russia 10/25/22 Coca-Cola sees 7%-8% currency headwind to FY23 EPS 10/25/22 Coca-Cola sees 8% currency headwind to Q4 revenue, consensus $9.8B $216.86 / +15.675 (+7.79%)
01/10/23 Icon sees FY23 adjusted EPS $12.40-$13.05, consensus $12.34 11/02/22 Icon reaffirms FY22 adjusted EPS view $11.65-$11.85, consensus $11.66 11/02/22 Icon reports Q3 EPS $3.00, consensus $2.94 07/27/22 Icon sees FY22 adjusted EPS $11.65-$11.85, consensus $11.58 11/30/22 Frontline reports Q3 adjusted EPS 37c vs. 21c last quarter 08/25/22 Frontline reports Q2 adjusted EPS 21c vs. (1c) last quarter 01/10/23 CVS Health reaffirms FY23 adjusted EPS view $8.70-$8.90, consensus $8.86 01/10/23 CVS Health reaffirms FY22 adjusted EPS view $8.55-$8.65, consensus $8.63 11/02/22 CVS Health sees FY23 adjusted EPS $8.70-$8.90, consensus $9.06 11/02/22 CVS Health raises FY22 revenue view to $309B-$314B from $307B-$312B 01/10/23 Coinbase sees FY22 adjusted EBITDA within negative $500M loss 'guardrail' 12/07/22 Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more 11/03/22 Coinbase reports Q3 EPS ($2.43), consensus ($2.40) 11/03/22 Notable companies reporting after market close 10/27/22 Capital One reports Q3 EPS $4.20, consensus $5.04 07/21/22 Capital One reports Q2 EPS $4.96, consensus $5.09 07/21/22 Notable companies reporting after market close 11/09/22 Bumble sees Q1 revenue $232M-$237M, consensus $254.46M 11/09/22 Bumble reports Q3 EPS 14c, consensus 1c 11/09/22 Notable companies reporting after market close 08/10/22 Bumble cuts FY22 revenue view to $920M-$930M from $934M-$944M 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 08/09/22 BioAtla reports Q2 net loss $28.9M vs. $30.4M last year 01/10/23 Bed Bath & Beyond reports Q3 adjusted EPS ($3.65), consensus ($2.11) 01/05/23 Bed Bath & Beyond sees Q3 net sales of about $1.26B, consensus $1.4B 09/29/22 Bed Bath & Beyond reports Q2 adjusted EPS ($3.22), consensus ($1.85) 09/28/22 Notable companies reporting before tomorrow's open 11/08/22 Bayer confirms Group outlook for 2022 11/08/22 Bayer reports Q3 core EPS EUR 1.13 vs. EUR 1.05 last year 08/04/22 Bayer raises FY core EPS view to EUR7.30 vs. EUR7.00 previously 08/04/22 Bayer reports Q2 core EPS EUR1.93 vs. EUR1.61 last year 10/26/22 Boeing reports Q3 core EPS ($6.18), consensus 2c 10/25/22 Notable companies reporting before tomorrow's open 07/27/22 Boeing reports Q2 core EPS (37c), consensus (16c) 12/08/22 Broadcom sees Q1 revenue $8.9B, consensus $8.79B 12/08/22 Broadcom reports Q4 EPS $10.45, consensus $10.28 12/08/22 Notable companies reporting after market close 09/01/22 Broadcom sees Q4 revenue $8.9B, consensus $8.73B 10/27/22 Amazon sees Q4 revenue $140B-$148B, consensus $155.15B 10/27/22 Amazon reports Q3 EPS 28c with Rivian gain, consensus 21c 07/28/22 Amazon reports Q2 AWS net sales $19.73B vs. $14.81B a year ago 01/10/23 Amarin sees Q4 revenue $88M-$90M, consensus $86.92M 10/27/22 Amarin continuing to suspend 2022 revenue guidance 10/27/22 Amarin reports Q3 adjusted EPS 2c, consensus (6c) 08/03/22 Amarin reports Q2 adjusted EPS (9c), consensus (6c) 10/19/22 Ally Financial sees Q4 adjusted EPS around $1.00, consensus $1.57 10/19/22 Ally Financial reports Q3 adjusted EPS $1.12, consensus $1.70 10/18/22 Notable companies reporting before tomorrow's open 01/10/23 Albertsons reports Q3 adjusted EPS 87c, consensus 67c 01/09/23 Notable companies reporting before tomorrow's open 10/18/22 Albertsons reports Q2 adjusted EPS 72c, consensus 65c 01/09/23 Accolade guides initial FY24 revenue around $410M, consensus $405.4M 01/09/23 Accolade narrows FY23 revenue view to $361M-$365M, consensus $359.2M 01/09/23 Accolade sees Q4 revenue $97M-$101M, consensus $101.7M 01/09/23 Accolade reports Q3 EPS (56c), consensus (62c) 10/27/22 Apple reports Q4 EPS $1.29, consensus $1.17 10/27/22 Notable companies reporting after market close 07/28/22 Apple reports Q3 EPS $1.20, consensus $1.16 07/28/22 Notable companies reporting after market close 11/21/22 Agilent sees FY23 adjusted EPS $5.61-$5.69, consensus $5.43 11/21/22 Agilent sees Q1 adjusted EPS $1.29-$1.31, consensus $1.31 11/21/22 Agilent reports Q4 adjusted EPS $1.53, consensus $1.39 11/21/22 Notable companies reporting after market close
On The Fly
Get caught up quickly on…
Show Hide Related Items >> <<
01/04/23 AT&T CFO Desroches says demand 'remains healthy' 01/04/23 AT&T CFO sees earnings and free cash flow growth in 2023 12/23/22 AT&T, BlackRock Alternatives to form commercial fiber platform joint venture 12/06/22 AT&T COO says company continues to see healthy demand 01/10/23 TD Synnex, Authomize partner for ITDR platform 01/10/23 TD Synnex announces $1B share repurchase pact 01/10/23 TD Synnex boosts dividend 17% to 35c per share 12/12/22 BIO-key, TD Synnex partner for identity-bound biometric MFA solutions $17.16 / +8.525 (+98.73%)
01/09/23 Sotera Health settles ethylene oxide litigation in Illinois for $408M 11/21/22 Sotera Health business Sterigenics issues statement on Fornek trial 11/21/22 Sotera Health trading resumes 11/21/22 Sotera Health jumps after Sterigenics found not liable for woman's cancer 08/04/22 Shake Shack sees FY22 domestic company-operated openings 35-40 07/13/22 Chairman of Shake Shack Daniel Meyer buys over $831K in shares RYAM Rayonier Advanced Materials 01/10/23 Rayonier Advanced Materials falls -28.3% 01/10/23 Rayonier Advanced Materials falls -19.7% 01/10/23 Rayonier Advanced Materials falls -11.6% 12/29/22 Rayonier: Force majeure by nat gas provider had $4M EBITDA impact to company 01/05/23 Iridium to partner t with Qualcomm on satellite messaging and emergency services 01/04/23 Visteon, Qualcomm collaborate on development of digital cockpit 11/02/22 Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates 01/06/23 Pfizer: FDA accepts for priority review sBLA for 20vPnC 01/05/23 3D Systems appoints Bruce to Medical Advisory Board 12/29/22 Pfizer discloses 5.38M share stake in Oric Pharmaceuticals 12/29/22 Pfizer announces topline results from Phase 3 study of fidanacogene elaparvovec 12/05/22 PepsiCo announces new global packaging goal 10/28/22 PepsiCo senior VP Gallagher sells 5,558 common shares 10/24/22 Keurig Dr Pepper names Sudhanshu Priyadarshi as CFO, effective November 14 10/13/22 Little Caesars, MTN DEW announce gaming combo, in-game items $29.03 / +6.455 (+28.59%)
01/10/23 Oak Street Health rises 28.5% 01/10/23 Oak Street Health rises 27.6% 01/10/23 Oak Street Health rises 31.8% 01/09/23 Oak Street Health jumps 26% after Bloomberg reports potential acquisition by CVS 01/09/23 Mondelez to release special edition Oreos with Xbox images 01/09/23 Microsoft acquires datacenter infrastructure company Fungible 01/06/23 NetEase acquires SkyBox Labs, terms not disclosed 12/28/22 Third Activision Blizzard video game unit seeks union 12/08/22 Tyson Foods appoints Melanie Boulden as CGO 11/14/22 Berkshire Hathaway adds TSMC, exits STORE Capital in Q3 10/13/22 Laser Photonics announces implementation of CleanTech Handheld Laser Blasting 10/10/22 VPX Sports, maker of Bang Energy drinks, seeks Chapter 11 bankruptcy protection $217.68 / +16.495 (+8.20%)
10/06/22 Icon selected by BARDA to execute an anthrax vaccine clinical trial 01/10/23 Frontline rises 24.7% 01/10/23 Frontline rises 17.1% 01/10/23 Frontline rises 21.7% 01/09/23 Frontline terminates combination agreement with Euronav 01/10/23 CVS Health saw flu vaccinations 'elevate a little bit' in latter part of 2022 01/10/23 CVS Health sees Signify Health deal closing in 1H, CEO says 01/10/23 CVS Health sees FY23 MA membership growth in LSD-MSD range 01/10/23 CVS Health repurchased 15M shares during Q4 at average share price of $99.99 01/10/23 Coinbase to cut workforce by about 950 employees in further restructuring 01/05/23 Cathie Wood's ARK Investment bought 172K shares of Coinbase today 01/04/23 Coinbase, NYDFS reach agreement to resolve compliance investigation 01/04/23 NY DFS announces $100M settlement with Coinbase 10/27/22 Capital One falls 5% to $97.15 after Q3 earnings miss estimates 10/12/22 BJ's Wholesale introduces new partnership with Capital One 08/24/22 Truist Financial appoints Scott Stanzel as EVP, CCO 07/21/22 Capital One drops 5% to $108.50 after Q2 results miss estimates 12/13/22 Match Group up 8% after Bloomberg report on Apple App store plans 11/13/22 Fly Intel: Top five weekend stock stories 11/10/22 Google expands its user choice billing pilot 11/09/22 Bumble down 18% after reporting Q3 earnings, giving Q4 guidance 01/10/23 BioAtla provides clinical program updates, 2023 milestones 11/04/22 BioAtla announces $65M underwritten offering of common stock 11/22/22 Best Buy rises 9.5% 11/22/22 Best Buy jumps 8% to $76.17 after Q3 earnings beat and comps outlook update 11/22/22 Best Buy sees FY23 comparable sales down approximately 10% 11/22/22 Genesco appoints Best Buy CFO Matthew Bilunas to board 01/10/23 Bed Bath & Beyond says identified additional $80M-$100M saving opportunity 01/10/23 Bed Bath & Beyond reports Q3 SSS down 32% 01/10/23 Bed Bath & Beyond reports liquidity of approximately $0.5B 01/10/23 Bed Bath & Beyond says Q3 net loss included $100.7M non-cash impairment charges 01/10/23 Boeing announces total Q4 deliveries 152 aircraft 01/10/23 Boeing delivered 110 737s in Q4, 2 747s 01/04/23 Gol Linhas sees 2023 revenue up about 32% y/y 12/28/22 Lockheed Martin, Boeing protest Army's decision to give Textron FLRAA contract $558.00 / -18.25 (-3.17%)
12/20/22 EU opens antitrust probe into Broadcom's proposed $61B VMware bid 12/15/22 Broadcom announces availability of CA 1 Flexible Storage soution 12/08/22 Broadcom reports Q4 cash from operations $4.583B, free cash flow $4.461M 12/08/22 Broadcom raises quarterly dividend 12% to $4.60 per share 01/09/23 Mattel's Fisher-Price re-announces recall of 4.7M Rock 'n Play Sleepers 01/06/23 Ceva's AFE solution now Alexa Voice Service qualified 01/05/23 GE HealthCare names Taha Kass-Hout CTO 01/05/23 Amazon up 1% after CEO confirms plan to eliminate just over 18,000 jobs 01/10/23 Amarin expects cash to support continued operations 01/10/23 Amarin announces 2022 achievements, 2023 priorities 01/10/23 Amarin appoints Stewart to board of directors 01/03/23 Amarin in patent infringement settlement with Health Net, no terms 10/19/22 Ally Financial sees Q4 as earnings 'low point' 10/19/22 Ally Financial down 7.7% after Q3 earnings and revenue miss 10/19/22 Ally Financial sees uncertainty ahead 10/18/22 Ally Financial says Jennifer LaClair departed from CFO position 01/02/23 Albertsons granted expedited review of special dividend restraining order 12/21/22 Albertsons says Washington State Supreme Court Set to hear appeal on February 9 12/21/22 Washington state AG files lawsuits against pharmacy chains over opioid crisis 12/06/22 Kroger expects to complete Albertsons merger in 'early 2024' 01/10/23 Jamf Holding helps 71,000 customers succeed with Apple 01/09/23 Qualcomm down 1% after Bloomberg report on Apple taking modem in-house 01/04/23 Apple fined EUR 8M by France's CNIL 12/26/22 Fly Intel: Top five weekend stock stories 01/09/23 Agilent authorizes $2B buyback authorization 01/09/23 Agilent invests $725M for manufacturing of therapeutic nucleic acids 01/06/23 Agilent, Akoya to develop diagnostic solutions for tissue analysis 12/15/22 Agilent VP Ancher-Jensen sells $4.6M of shares 01/10/23 Wedbush December quarter checks for Microsoft's Azure 'stable,' says Wedbush 01/10/23 Barclays Microsoft price target lowered to $280 from $296 at Barclays 01/09/23 Piper Sandler Microsoft price target lowered to $247 from $265 at Piper Sandler 01/05/23 Oppenheimer Oppenheimer sees Microsoft leveraging ChatGPT white-space potential 01/10/23 Piper Sandler Piper Sandler sees no strategic reason for Apple to insource Wi-Fi combo chip 01/10/23 BofA Broadcom loss of Apple socket immaterial for 2-plus years, says BofA 01/09/23 Bernstein Apple price target lowered to $125 from $170 at Bernstein 01/09/23 Wells Fargo Qorvo price target raised to $90 from $80 at Wells Fargo $558.00 / -18.25 (-3.17%)
12/27/22 Piper Sandler Piper reveals top cloud automation software picks heading into 2023 12/14/22 Deutsche Bank Broadcom price target raised to $590 from $575 at Deutsche Bank 01/09/23 BWS Financial Iridium price target raised to $75 from $60 at BWS Financial 01/06/23 William Blair William Blair sees Iridium rallying after 'transformational' partnership 01/05/23 Wells Fargo Wells halves Bed Bath & Beyond target to $1, says bankruptcy may be 'imminent' 11/28/22 Wedbush Black Friday winners Include Best Buy, losers include Pets, says Wedbush 09/30/22 Odeon Capital Odeon upgrades Bed Bath & Beyond to Hold with things 'moving in right direction' 09/30/22 Odeon Capital Bed Bath & Beyond upgraded to Hold from Sell at Odeon Capital 01/09/23 Jefferies Coinbase initiated with a Hold at Jefferies 01/09/23 Wells Fargo Coinbase price target lowered to $33 from $55 at Wells Fargo 01/09/23 JMP Securities Coinbase price target lowered to $80 from $155 at JMP Securities 01/05/23 TD Cowen Cowen downgrades Coinbase on low visibility into trading recovery 01/10/23 DA Davidson Accolade price target lowered to $14 from $16 at DA Davidson 01/10/23 Canaccord Accolade price target lowered to $14 from $17 at Canaccord 12/27/22 Piper Sandler Piper views TriCare T-5 contract awards as neutral for Accolade 10/04/22 Needham Accolade price target raised to $15 from $12 at Needham 01/10/23 Morgan Stanley Boeing downgraded to Equal Weight from Overweight at Morgan Stanley 01/03/23 Baird Boeing price target raised to $250 from $210 at Baird 12/14/22 Susquehanna Boeing price target raised to $217 from $185 at Susquehanna 12/08/22 Wells Fargo Boeing price target raised to $218 from $185 at Wells Fargo 01/10/23 Citi Citi adds AT&T, Equinix to 'Positive Catalyst Watch List' 01/10/23 Wells Fargo AT&T upgraded to Overweight from Equal Weight at Wells Fargo 12/27/22 Raymond James Raymond James sees 'solid benefits' to AT&T from BlackRock venture 12/23/22 KeyBanc AT&T-BlackRock fiber JV a 'material positive' for Dycom, says KeyBanc 01/10/23 Wells Fargo Wells Fargo upgrades Agilent to Overweight, raises price target to $170 01/10/23 Wells Fargo Agilent upgraded to Overweight from Equal Weight at Wells Fargo 01/06/23 Gordon Haskett wonders if Guardant could be 'shoehorned' into Agilent search 11/22/22 Jefferies Agilent price target raised to $168 from $158 at Jefferies 01/10/23 KeyBanc KeyBanc upgrades Bumble on confidence in revenue growth 01/09/23 KeyBanc Bumble upgraded to Overweight from Sector Weight at KeyBanc 12/12/22 BofA Bumble initiated with a Buy at BofA 12/08/22 UBS UBS starts Bumble at Neutral, sees international opportunity offset saturation 01/10/23 JPMorgan Capital One price target lowered to $124 from $126 at JPMorgan 01/10/23 Jefferies Capital One downgraded to Hold from Buy at Jefferies 01/05/23 Stephens Capital One downgraded to Underweight at Stephens on auto lending concerns 01/05/23 Stephens Capital One downgraded to Underweight from Equal Weight at Stephens 01/10/23 JPMorgan Ally Financial price target lowered to $27 from $30 at JPMorgan 01/10/23 Jefferies Ally Financial downgraded to Hold from Buy at Jefferies 01/09/23 Piper Sandler Ally Financial upgraded to Neutral from Underweight at Piper Sandler 01/10/23 Stifel Oak Street Health, CVS deal would make sense for both companies, says Stifel 01/10/23 Piper Sandler Takeout report adds 'intrigue' to Oak Street story, says Piper Sandler 01/05/23 Wells Fargo NY, NC opportunities could be 1% tailwind to CVS EPS, says Wells Fargo 01/04/23 BofA Amwell upgraded to Buy at BofA with anchor clients signed $29.03 / +6.455 (+28.59%)
11/21/22 Raymond James Oak Street Health downgraded to Market Perform from Outperform at Raymond James 11/21/22 Raymond James Oak Street Health downgraded to Market Perform from Outperform at Raymond James 12/19/22 Credit Suisse Best Buy initiated with a Neutral at Credit Suisse 12/14/22 BofA Best Buy downgraded to Underperform at BofA on challenging demand environment 12/14/22 BofA Best Buy downgraded to Underperform from Neutral at BofA 12/12/22 Goldman Sachs Best Buy upgraded to Neutral from Sell at Goldman Sachs 01/06/23 MKM Partners MKM Partners sees WWE as 'very attractive asset' if it goes for sale 01/05/23 BofA Amazon layoffs 'not a positive signal,' but 'good for sentiment,' says BofA 01/04/23 UBS Amazon.com price target lowered to $125 from $165 at UBS 01/04/23 Needham Needham cuts Overstock.com to Hold, sees company as 'share donor' post pandemic 12/20/22 Atlantic Equities Coca-Cola, Pepsi remain preferred beverage names at Atlantic Equities 12/06/22 Deutsche Bank Coca-Cola price target raised to $62 from $59 at Deutsche Bank 11/04/22 Redburn PepsiCo initiated with a Sell at Redburn 10/26/22 UBS Coca-Cola price target raised to $68 from $63 at UBS 12/07/22 Argus PepsiCo price target raised to $206 from $195 at Argus 12/06/22 Deutsche Bank PepsiCo price target raised to $186 from $181 at Deutsche Bank 01/05/23 Morgan Stanley Morgan Stanley sees Moderna's phase 3 RSV vaccine data as catalyst-driven idea 01/04/23 BofA BioMarin price target raised to $200, added to 'US 1 List' at BofA 01/04/23 BofA Pfizer downgraded to Neutral at BofA on COVID-19 uncertainty 01/04/23 BofA Pfizer downgraded to Neutral from Buy at BofA $17.16 / +8.525 (+98.73%)
01/10/23 Wolfe Research Sotera Health 'to rock' with 'massive overhang' removed, says Wolfe Research 11/15/22 Barclays Sotera Health downgraded to Underweight from Equal Weight at Barclays 11/03/22 RBC Capital Sotera Health price target lowered to $8 from $25 at RBC Capital 10/06/22 Barclays Sotera Health price target lowered to $8 from $22 at Barclays 01/05/23 Barclays Shake Shack price target lowered to $42 from $46 at Barclays 12/21/22 Wedbush Shake Shack downgraded to Neutral from Outperform at Wedbush 12/21/22 Wedbush Shake Shack downgraded to Neutral from Outperform at Wedbush 11/07/22 Deutsche Bank Shake Shack price target raised to $56 from $53 at Deutsche Bank $217.68 / +16.495 (+8.20%)
12/21/22 Baird Icon price target lowered to $260 from $265 at Baird 11/09/22 BofA Icon upgraded to Buy from Neutral at BofA 10/18/22 Deutsche Bank Icon price target lowered to $280 from $295 at Deutsche Bank 10/10/22 Guggenheim Iqvia price target lowered to $234 from $246 at Guggenheim 01/04/23 Wells Fargo Albertsons price target lowered to $22 from $30 at Wells Fargo 12/19/22 Credit Suisse Albertsons assumed with Restricted rating at Credit Suisse 12/06/22 Bernstein Albertsons initiated with an Outperform at Bernstein 12/05/22 Jefferies Kroger price target raised to $50 from $45 at Jefferies 12/21/22 Citi Citi reveals top IT hardware stock picks for 2023 10/12/22 Raymond James TD Synnex added to Analyst Current Favorites list at Raymond James 10/04/22 RBC Capital TD Synnex initiated with a Sector Perform at RBC Capital 09/28/22 Barrington TD Synnex price target lowered to $98 from $106 at Barrington 01/06/23 Jefferies Jefferies upgrades 'intriguing small cap value play' Amarin to Buy 01/06/23 Jefferies Amarin upgraded to Buy from Hold at Jefferies 05/06/22 JPMorgan JPMorgan downgrades Amarin to sell on headwinds in U.S., Europe 05/06/22 JPMorgan Amarin downgraded to Underweight from Neutral at JPMorgan 01/10/23 Stifel Euronav NV downgraded to Hold from Buy at Stifel 11/29/22 Jefferies Frontline price target raised to $17 from $16 at Jefferies 10/27/22 Deutsche Bank Frontline price target raised to $15 from $12 at Deutsche Bank 09/06/22 Deutsche Bank Frontline price target raised to $12 from $7 at Deutsche Bank 01/04/23 EF Hutton BioAtla initiated with a Buy at EF Hutton 09/15/22 JMP Securities BioAtla initiated with an Outperform at JMP Securities 08/10/22 H.C. Wainwright BioAtla price target lowered to $20 from $25 at H.C. Wainwright 05/05/22 Credit Suisse BioAtla downgraded to Neutral from Outperform at Credit Suisse RYAM Rayonier Advanced Materials 01/09/23 RBC Capital Rayonier Advanced Materials cut to Sector Perform at RBC Capital on valuation 01/09/23 RBC Capital Rayonier Advanced downgraded to Sector Perform from Outperform at RBC Capital 10/13/22 BofA Rayonier Advanced Materials price target lowered to $1.90 from $2.60 at BofA 07/18/22 RBC Capital Rayonier Advanced Materials upgraded to Outperform at RBC Capital 10/20/22 AT&T raises FY22 adjusted cont ops EPS view to '$2.50 or higher' 10/20/22 AT&T reports Q3 adjusted EPS 68c, consensus 61c 10/19/22 Notable companies reporting before tomorrow's open 01/10/23 TD Synnex sees Q1 EPS $2.60-$3.00, consensus $3.05 01/10/23 TD Synnex reports Q4 EPS $3.44, consensus $2.91 09/27/22 TD Synnex sees Q4 EPS $2.70-$3.10, consensus $2.73 09/27/22 TD Synnex reports Q3 EPS $2.74, consensus $2.73 $17.16 / +8.525 (+98.73%)
11/02/22 Sotera Health lowers FY22 adjusted EPS view to 91c-95c from 93c-97c 11/02/22 Sotera Health reports Q3 adjusted EPS 23c, consensus 22c 08/04/22 Sotera Health narrows FY22 adjusted EPS guidance to 93c-97c from 93c-99c 08/04/22 Sotera Health reports Q2 adjusted EPS 27c, consensus 24c 01/10/23 Shake Shack reports preliminary Q4 revenue $238.5M, consensus $237.56M 11/03/22 Shake Shack reports Q3 adjusted EPS (6c), consensus (6c) 08/04/22 Shake Shack sees Q3 revenue $221M-$226.5M consensus $245M 08/04/22 Shake Shack reports Q2 EPS 0c vs. 5c last year RYAM Rayonier Advanced Materials 11/01/22 Rayonier Advanced Materials reports Q3 EPS 45c, two estimates 10c 08/03/22 Rayonier Advanced Materials reports Q2 continuing ops EPS (39c), consensus (16c) 11/02/22 Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42 11/02/22 Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13 11/02/22 Notable companies reporting after market close 07/27/22 Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23 01/09/23 Pfizer sees 2025 potential non-COVID revenues excluding BD of about $52B 11/01/22 Pfizer raises FY22 adjusted EPS view to $6.40-$6.50 from $6.30-$6.45 11/01/22 Pfizer reports Q3 adjusted EPS $1.78, consensus $1.39 10/31/22 Notable companies reporting before tomorrow's open 10/12/22 PepsiCo raises FY22 core EPS view to approx. $6.73 from $6.63 10/12/22 PepsiCo raises FY22 core constant currency EPS growth view to 10% from 8% 10/12/22 PepsiCo reports Q3 core EPS $1.97, consensus $1.84 10/11/22 Notable companies reporting before tomorrow's open $29.03 / +6.455 (+28.59%)
01/09/23 Oak Street Health sees FY23 revenue $3.0B-$3.15B, consensus $3.05B 01/09/23 Oak Street Health raises FY22 revenue view to at or above $2.155B 11/07/22 Oak Street Health reports Q3 EPS (56c), consensus (61c) 08/02/22 Oak Street Health raises FY22 revenue $2.125B-$2.145B from $2.1B-$2.135B 10/25/22 Microsoft sees FX decreasing total revenue growth by 5% in FY23 10/25/22 Microsoft reports Q1 EPS $2.35, consensus $2.30 10/25/22 Notable companies reporting after market close 07/26/22 Microsoft sees FY23 revenue growth in double digits, consensus $225.98B 10/25/22 Coca-Cola sees FY22 comparable EPS up 6%-7%, consensus $2.46 10/25/22 Coca-Cola sees 1% impact to FY22 net revenues, operating income from Russia 10/25/22 Coca-Cola sees 7%-8% currency headwind to FY23 EPS 10/25/22 Coca-Cola sees 8% currency headwind to Q4 revenue, consensus $9.8B $217.68 / +16.495 (+8.20%)
01/10/23 Icon sees FY23 adjusted EPS $12.40-$13.05, consensus $12.34 11/02/22 Icon reaffirms FY22 adjusted EPS view $11.65-$11.85, consensus $11.66 11/02/22 Icon reports Q3 EPS $3.00, consensus $2.94 07/27/22 Icon sees FY22 adjusted EPS $11.65-$11.85, consensus $11.58 11/30/22 Frontline reports Q3 adjusted EPS 37c vs. 21c last quarter 08/25/22 Frontline reports Q2 adjusted EPS 21c vs. (1c) last quarter 01/10/23 CVS Health reaffirms FY23 adjusted EPS view $8.70-$8.90, consensus $8.86 01/10/23 CVS Health reaffirms FY22 adjusted EPS view $8.55-$8.65, consensus $8.63 11/02/22 CVS Health sees FY23 adjusted EPS $8.70-$8.90, consensus $9.06 11/02/22 CVS Health raises FY22 revenue view to $309B-$314B from $307B-$312B 01/10/23 Coinbase sees FY22 adjusted EBITDA within negative $500M loss 'guardrail' 12/07/22 Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more 11/03/22 Coinbase reports Q3 EPS ($2.43), consensus ($2.40) 11/03/22 Notable companies reporting after market close 10/27/22 Capital One reports Q3 EPS $4.20, consensus $5.04 07/21/22 Capital One reports Q2 EPS $4.96, consensus $5.09 07/21/22 Notable companies reporting after market close 11/09/22 Bumble sees Q1 revenue $232M-$237M, consensus $254.46M 11/09/22 Bumble reports Q3 EPS 14c, consensus 1c 11/09/22 Notable companies reporting after market close 08/10/22 Bumble cuts FY22 revenue view to $920M-$930M from $934M-$944M 11/03/22 BioAtla reports Q3 $25.8M compared to a net loss of $22.9M in Q321 08/09/22 BioAtla reports Q2 net loss $28.9M vs. $30.4M last year 11/22/22 Best Buy reports Q3 EPS $1.38, consensus $1.03 11/21/22 Notable companies reporting before tomorrow's open 08/30/22 Best Buy reports Q2 EPS$1.54, consensus $1.27 01/10/23 Bed Bath & Beyond reports Q3 adjusted EPS ($3.65), consensus ($2.11) 01/05/23 Bed Bath & Beyond sees Q3 net sales of about $1.26B, consensus $1.4B 09/29/22 Bed Bath & Beyond reports Q2 adjusted EPS ($3.22), consensus ($1.85) 09/28/22 Notable companies reporting before tomorrow's open 10/26/22 Boeing reports Q3 core EPS ($6.18), consensus 2c 10/25/22 Notable companies reporting before tomorrow's open 07/27/22 Boeing reports Q2 core EPS (37c), consensus (16c) $558.00 / -18.25 (-3.17%)
12/08/22 Broadcom sees Q1 revenue $8.9B, consensus $8.79B 12/08/22 Broadcom reports Q4 EPS $10.45, consensus $10.28 12/08/22 Notable companies reporting after market close 09/01/22 Broadcom sees Q4 revenue $8.9B, consensus $8.73B 10/27/22 Amazon sees Q4 revenue $140B-$148B, consensus $155.15B 10/27/22 Amazon reports Q3 EPS 28c with Rivian gain, consensus 21c 07/28/22 Amazon reports Q2 AWS net sales $19.73B vs. $14.81B a year ago 01/10/23 Amarin sees Q4 revenue $88M-$90M, consensus $86.92M 10/27/22 Amarin continuing to suspend 2022 revenue guidance 10/27/22 Amarin reports Q3 adjusted EPS 2c, consensus (6c) 08/03/22 Amarin reports Q2 adjusted EPS (9c), consensus (6c) 10/19/22 Ally Financial sees Q4 adjusted EPS around $1.00, consensus $1.57 10/19/22 Ally Financial reports Q3 adjusted EPS $1.12, consensus $1.70 10/18/22 Notable companies reporting before tomorrow's open 01/10/23 Albertsons reports Q3 adjusted EPS 87c, consensus 67c 01/09/23 Notable companies reporting before tomorrow's open 10/18/22 Albertsons reports Q2 adjusted EPS 72c, consensus 65c 01/09/23 Accolade guides initial FY24 revenue around $410M, consensus $405.4M 01/09/23 Accolade narrows FY23 revenue view to $361M-$365M, consensus $359.2M 01/09/23 Accolade sees Q4 revenue $97M-$101M, consensus $101.7M 01/09/23 Accolade reports Q3 EPS (56c), consensus (62c) 10/27/22 Apple reports Q4 EPS $1.29, consensus $1.17 10/27/22 Notable companies reporting after market close 07/28/22 Apple reports Q3 EPS $1.20, consensus $1.16 07/28/22 Notable companies reporting after market close 11/21/22 Agilent sees FY23 adjusted EPS $5.61-$5.69, consensus $5.43 11/21/22 Agilent sees Q1 adjusted EPS $1.29-$1.31, consensus $1.31 11/21/22 Agilent reports Q4 adjusted EPS $1.53, consensus $1.39 11/21/22 Notable companies reporting after market close
